|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 11,091,459
U.S. Patent No. 11,091,459, granted on August 17, 2021, to Bristol-Myers Squibb Company, covers a pharmaceutical composition for treating or preventing a disease or condition. The patent asserts claims related to specific formulations of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and its use in combination therapies. The patent landscape surrounding nivolumab is complex, with numerous related patents and ongoing litigation.
What is the Core Technology Covered by U.S. Patent No. 11,091,459?
The patent's core technology focuses on a pharmaceutical composition comprising nivolumab in a specific formulation. This formulation is designed to enhance the stability, efficacy, or administration of the antibody drug.
- Active Ingredient: Nivolumab, a human immunoglobulin G4 (IgG4) kappa isotype monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade is intended to restore T-cell antitumor immune activity.
- Formulation Details: The patent claims describe specific characteristics of the pharmaceutical composition, which may include buffer components, stabilizers, pH ranges, and concentrations. These details are crucial for maintaining the antibody's structural integrity and biological activity over time and during administration.
- Therapeutic Applications: The patent claims cover the use of this specific formulation for treating or preventing diseases or conditions that can be ameliorated by PD-1 blockade. This primarily includes various types of cancer, such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma.
What Specific Claims Does U.S. Patent No. 11,091,459 Assert?
U.S. Patent No. 11,091,459 contains a series of independent and dependent claims that define the scope of protection. The claims are structured to cover both the composition itself and its methods of use.
- Claim 1 (Independent): This claim typically defines the core pharmaceutical composition. For example, it may claim a pharmaceutical composition comprising nivolumab and specific excipients at defined concentrations and pH. The claim would specify the antibody's properties, such as its binding affinity to PD-1.
- Dependent Claims: These claims narrow the scope of the independent claims by adding further limitations. They might specify:
- The concentration of nivolumab (e.g., 10 mg/mL).
- The specific buffer system used (e.g., a histidine-acetate buffer).
- The presence of specific stabilizers (e.g., polysorbate 80, sucrose).
- A specific pH range for the composition (e.g., pH 5.5 to 6.5).
- The form of the composition (e.g., liquid formulation suitable for intravenous infusion).
- The method of manufacturing the composition.
- Method of Use Claims: These claims would cover the use of the claimed composition for treating specific diseases.
- A method of treating a patient suffering from cancer, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition.
- Specific cancer types may be listed, such as melanoma, NSCLC, or renal cell carcinoma.
- The patent may also include claims related to combination therapies, where the nivolumab formulation is administered with other therapeutic agents.
How Does the Formulation in Patent 11,091,459 Differ from Other Nivolumab Formulations?
The patent's claims define a specific set of parameters for the nivolumab formulation. Differences from other formulations would lie in the precise combination and concentration of excipients, buffer systems, pH, and other physicochemical properties.
- Excipient Composition: Patent 11,091,459 likely specifies a unique blend of stabilizers and buffering agents that contribute to the long-term stability and injectability of the nivolumab antibody. Other formulations might use different or absent stabilizers, leading to variations in shelf-life or administration protocols.
- pH Range: The optimal pH for antibody stability and efficacy is critical. The patent will claim a narrow pH range that Bristol-Myers Squibb found to be particularly advantageous for its nivolumab product.
- Concentration: The concentration of nivolumab in the formulation is also a key aspect, impacting dosage and administration volume. Variations in concentration may necessitate different infusion rates or schedules.
- Manufacturing Process: While not always explicitly claimed, the patent might implicitly or explicitly cover aspects of the manufacturing process that yield the claimed formulation, potentially offering a competitive advantage in production.
What is the Current Patent Landscape for Nivolumab?
The patent landscape for nivolumab is extensive and competitive, involving multiple patents covering the antibody itself, its manufacturing, specific formulations, and therapeutic uses. Bristol-Myers Squibb holds a significant portfolio of patents related to nivolumab.
- Composition of Matter Patents: These are foundational patents covering the nivolumab antibody molecule itself. These patents have earlier expiration dates and are critical for market exclusivity.
- Formulation Patents: Patents like 11,091,459 focus on specific compositions of the drug product, extending market exclusivity beyond the initial composition of matter patents.
- Method of Use Patents: These patents cover the use of nivolumab for treating specific indications, often granted sequentially as new therapeutic applications are discovered and approved.
- Manufacturing Patents: Patents related to the process of producing nivolumab can also be significant, particularly for biosimilar developers.
- Patent Expirations: Key patents for nivolumab, including composition of matter patents, have expiration dates that dictate when biosimilar versions can enter the market. For instance, core patents for nivolumab have been subject to litigation and potential early expiration challenges.
- Inter Partes Review (IPR) and Litigation: The nivolumab patent portfolio has been subject to numerous challenges through IPRs at the U.S. Patent and Trademark Office (USPTO) and patent litigation in federal courts. These proceedings aim to invalidate or challenge the scope of existing patents, often by generic or biosimilar manufacturers seeking to enter the market. For example, numerous challenges have targeted foundational patents held by Bristol-Myers Squibb.
What are the Potential Implications of U.S. Patent No. 11,091,459 for Competitors and Investors?
This patent has direct implications for companies developing or marketing biosimilar versions of nivolumab and for investors assessing market opportunities.
- Biosimilar Development: Companies seeking to launch a biosimilar nivolumab must navigate this patent. They will need to demonstrate that their product does not infringe on the claims of 11,091,459, potentially by developing a different formulation or arguing that their formulation falls outside the patent's scope. This could involve significant R&D investment.
- Market Exclusivity: Formulation patents like this one can extend the effective market exclusivity for the branded drug beyond the expiration of primary composition of matter patents. This protects revenue streams for the patent holder.
- Litigation Risk: Competitors may challenge the validity or enforceability of this patent through litigation or administrative proceedings like IPRs. Investors should monitor such activities.
- Investment Decisions: For investors, understanding the breadth of patents like 11,091,459 is crucial for forecasting market entry timelines for biosimilars and the potential profitability of both branded and generic/biosimilar products. It influences the perceived risk and reward of investing in companies within the oncology therapeutic space.
- Licensing Opportunities: The patent could represent an opportunity for licensing if other entities wish to utilize the specific formulation.
How is Nivolumab Currently Marketed, and What Diseases Does It Treat?
Nivolumab is marketed by Bristol-Myers Squibb under the brand name Opdivo. It is approved for a range of cancer types, utilizing its mechanism of action to reactivate the body's immune system against cancer cells.
- Brand Name: Opdivo (nivolumab)
- Mechanism of Action: PD-1 checkpoint inhibitor. It blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing T-cells to attack cancer cells.
- Approved Indications:
- Metastatic melanoma: As adjuvant therapy after complete resection, and for unresectable or metastatic melanoma.
- Non-small cell lung cancer (NSCLC): For metastatic NSCLC, and in combination with ipilimumab for first-line treatment of metastatic or recurrent NSCLC.
- Renal cell carcinoma (RCC): For advanced RCC after prior therapy.
- Classical Hodgkin lymphoma: For adult and pediatric patients with relapsed or refractory classical Hodgkin lymphoma.
- Squamous cell carcinoma of the head and neck (SCCHN): For recurrent or metastatic SCCHN with progression on or after platinum-based chemotherapy.
- Urothelial carcinoma: For locally advanced or metastatic urothelial carcinoma that has progressed during or after platinum-based chemotherapy or has progressed within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.
- Colorectal cancer (CRC): For patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic CRC.
- Hepatocellular carcinoma (HCC): For patients with HCC who have been previously treated with sorafenib.
What is the Status of Patent 11,091,459 and Related Patent Challenges?
Patent 11,091,459 is an active, granted U.S. patent. Its status as a formulation patent means it is likely to be a target for biosimilar manufacturers looking to design around existing intellectual property.
- Patent Term: The patent term for U.S. patents generally extends 20 years from the filing date, subject to potential adjustments and extensions. For utility patents filed on or after June 8, 1995, the term is 20 years from the application filing date. Given the grant date of August 17, 2021, the patent is likely to remain in force for a significant period.
- Infringement Analysis: Competitors would need to conduct a thorough freedom-to-operate analysis to determine if their proposed nivolumab product infringes on the claims of 11,091,459.
- Potential Challenges: While specific challenges to patent 11,091,459 may not be publicly detailed at this early stage, it is common for such formulation patents protecting blockbuster drugs to face challenges through:
- Inter Partes Review (IPR): A post-grant review proceeding before the USPTO Patent Trial and Appeal Board (PTAB) where a third party can challenge the validity of patent claims.
- Declaratory Judgment Actions: Lawsuits filed by potential infringers seeking a court ruling that the patent is invalid or not infringed.
- Patent Litigation: If Bristol-Myers Squibb or its licensees sue a competitor for infringement, the competitor may counterclaim for invalidity.
Key Takeaways
- U.S. Patent No. 11,091,459 protects a specific pharmaceutical formulation of nivolumab, an important PD-1 inhibitor, and its therapeutic uses.
- The patent's claims focus on detailed compositional aspects of the nivolumab drug product, aiming to secure extended market exclusivity.
- Nivolumab (Opdivo) is a widely used oncology drug for multiple cancer types, making its patent landscape critical for market dynamics.
- The patent portfolio surrounding nivolumab is extensive and has been subject to significant legal challenges, including IPRs and litigation, by entities seeking to market biosimilars.
- Companies developing biosimilar nivolumab must carefully analyze patent 11,091,459 and may need to develop alternative formulations to avoid infringement.
- Investors should monitor ongoing patent challenges and litigation to assess future market competition and revenue projections for both branded and biosimilar products.
Frequently Asked Questions
-
When does U.S. Patent No. 11,091,459 expire?
The patent term for U.S. patents is generally 20 years from the filing date. Specific expiration can be determined by finding the filing date of the patent application that led to this patent and adding 20 years, subject to potential adjustments.
-
Can biosimilar manufacturers use the exact same formulation protected by Patent 11,091,459?
No, biosimilar manufacturers are generally prohibited from using an identical formulation if it infringes on the patent claims. They typically must develop a formulation that is demonstrated to be "highly similar" to the reference product but does not infringe on existing patents covering specific formulations.
-
What is the primary impact of formulation patents like 11,091,459 on the drug market?
Formulation patents serve to extend the period of market exclusivity for a drug beyond the expiration of its primary composition of matter patents, thereby protecting the innovator company's revenue stream and influencing the timing of biosimilar market entry.
-
Are there other active patents covering nivolumab formulations?
Yes, Bristol-Myers Squibb holds multiple patents covering various aspects of nivolumab, including different formulations, manufacturing processes, and therapeutic uses. U.S. Patent No. 11,091,459 represents one specific formulation patent within a broader intellectual property strategy.
-
How can a company determine if its nivolumab formulation infringes Patent 11,091,459?
A comprehensive freedom-to-operate (FTO) analysis is required. This involves a detailed comparison of the proposed formulation's specific components, concentrations, pH, and other defined characteristics against the language and scope of the patent's claims. Legal counsel specializing in patent law is essential for this assessment.
Citations
[1] Bristol-Myers Squibb Company. (2021). Pharmaceutical composition comprising a PD-1 blocking antibody. U.S. Patent No. 11,091,459. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
